Article History

Received: 12 June 2017

Accepted: 11 October 2017

First Online: 13 November 2017

Change Date: 12 June 2018

Change Type: Correction

Change Details: In the version of this Article originally published, the authors described the ANT compound used in their study as 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid (ANT). The authors now wish to clarify that the ANT compound used was actually a 2,5-dimethylpyrrolyl benzoic acid derivative¹ that has been shown to inhibit not only the enzymatic activity of EphA2, but also several unrelated enzymes². The description of the compound in the Article has now been changed to 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid derivative (ANT) to reflect this.

Change Date: 13 February 2018

Change Type: Correction

Change Details: In the version of this Article originally published, technical problems led to errors in Figs. 2d and 5b. In the western blot panel in Fig. 2d, actin bands were misaligned at the bottom of the image and did not line up with the other bands in the panel; the corrected figure is shown below. In Fig. 5b, the upper right panel had an incorrect title of ‘CXCL3/KC’; it should have instead been ‘CXCL1/KC’. These errors have now been corrected in all versions of the Article.

Competing interests

: S.G.F. is a co-founder of and shareholder in NovaDigm Therapeutics, Inc., a company that is developing a vaccine against mucosal and invasive <i>Candida</i> infections.